Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pliant Therapeutics, Inc. - Common Stock (NQ:PLRX)

0.9828 -0.0072 (-0.73%)
Delayed Quote Updated: 12:23 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Pliant Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
United Therapeutics Surges 14% on Groundbreaking Tyvaso Phase 3 Results for IPF
In a landmark moment for respiratory medicine and biotechnology, United Therapeutics (NASDAQ:UTHR) announced late Monday, March 30, 2026, that its pivotal TETON-1 Phase 3 study for nebulized Tyvaso... 
Via MarketMinute
News headline image
Keep an eye on the top gainers and losers in Thursday's session. ↗
Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Get insights into the top gainers and losers of Friday's after-hours session. ↗
Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Pliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types ↗
Pliant Therapeutics' PLN-101095 showed partial responses in ICI-refractory tumors, with a 50% ORR at the highest dose tested in its Phase 1 trial. 
Via Benzinga
News headline image
What's going on in today's after hours session ↗
After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
News headline image
Pliant Therapeutics Drops IPF Drug Trial After Review, Analyst Flags Uncertain Future ↗
Pliant Therapeutics ends its Phase 2b IPF trial for bexotegrast, prompting a Needham downgrade to Hold due to limited catalysts and pipeline challenges. 
Via Benzinga
News headline image
This Teleflex Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday ↗
 
Via Benzinga
News headline image
Get insights into the top gainers and losers of Monday's after-hours session. ↗
Discover the top movers in Monday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
News headline image
Here are the top movers in Monday's session. ↗
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Pliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung Disorder ↗
Pliant Therapeutics discontinued its BEACON-IPF trial for bexotegrast due to safety concerns but observed early efficacy. The company plans further data analysis. 
Via Benzinga
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Which stocks are gapping on Monday? ↗
Traders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
News headline image
Unusual volume stocks in Wednesday's session ↗
On Wednesday, there are stocks with unusual volume. Let's take a look. 
Via Chartmill
News headline image
Which stocks are experiencing notable movement on Monday? ↗
Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
Crude Oil Rises Sharply; Manhattan Associates Shares Slide ↗
 
Via Benzinga
News headline image
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Nasdaq Surges 1%; ON Semiconductor Shares Plunge Following Earnings Miss ↗
 
Via Benzinga
News headline image
This Illumina Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday ↗
 
Via Benzinga
News headline image
The market is filled with gapping stocks in Monday's session. ↗
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
News headline image
Dow Gains 100 Points; McDonald's Shares Rise After Q4 Results ↗
 
Via Benzinga
Topics Stocks
News headline image
Monday's pre-market session: top gainers and losers ↗
Wondering what's happening in Monday's pre-market session? Find an overview in this article. 
Via Chartmill
News headline image
Pliant Therapeutics Pauses Lead Product Mid-Stage Trial In Patients With Stiff Lung Tissues ↗
Pliant Therapeutics halted new enrollment in its BEACON-IPF trial after a safety board review. A separate study showed bexotegrast reduced lung collagen. 
Via Benzinga
News headline image
Tesla, ON Semiconductor And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why BP Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why RH Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
PLRX Stock Earnings: Pliant Therapeutics Misses EPS for Q2 2024 ↗
PLRX stock results show that Pliant Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.